CN105073121B - 半透性多孔人造痂的形成 - Google Patents

半透性多孔人造痂的形成 Download PDF

Info

Publication number
CN105073121B
CN105073121B CN201380068529.0A CN201380068529A CN105073121B CN 105073121 B CN105073121 B CN 105073121B CN 201380068529 A CN201380068529 A CN 201380068529A CN 105073121 B CN105073121 B CN 105073121B
Authority
CN
China
Prior art keywords
scab
semi
gauze
permeable porous
artificial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380068529.0A
Other languages
English (en)
Other versions
CN105073121A (zh
Inventor
帕西法尔·维嘉·比亚维森西奥
米格尔·埃德加多·巴蒂斯塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN105073121A publication Critical patent/CN105073121A/zh
Application granted granted Critical
Publication of CN105073121B publication Critical patent/CN105073121B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0085—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A61L2300/222—Steroids, e.g. corticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/43—Hormones, e.g. dexamethasone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/442—Colorants, dyes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)

Abstract

一种自固定半透性多孔人造痂，用于保护侵蚀或损坏表面。它可以应用于对任何生命体(包括植物)。通过酶催化反应裂解的细胞释放作用在所应用的受损区域上形成该痂的聚合网状物。在该保护区表面下，促进新的正常细胞生长，其可以自由呼吸，无需干燥。它可以防止水、电解质和蛋白质的流失，还可以防止感染，可取代纱布和敷料的使用，纱布和敷料在去除时会伤害新皮肤的。该红色水性混合物通过刷涂或喷涂应用，其具有触变性质，通过在容器中的下列化合物的物理化学相互作用获得：1～5g％偶氮磺酰胺+0.004～0.007g％的龙胆紫+0.001～0.003g％的地塞米松+0.5～2g％的泛醇+0.03～0.06g％的庆大霉素。

Description

半透性多孔人造痂的形成
1.技术领域
本发明涉及人造治愈装置，在去除坏死组织并对受损区或烧伤区消毒之后，可以将该人造治愈装置应用在受损表面、伤口、A-AB型烧伤处。
2.背景技术
该技术包括：去除受伤区的坏死组织，然后使用在标题中提到的人工覆盖物。该准备(preparado)可以促使在受伤表面上形成人造痂。
要解决的问题是：
1.取代纱布的使用，因为纱布粘附在受损区域，当试图将纱布去除时，会在造粒区引起损伤，从而导致缺陷性结疤。
2.避免因保护外部生物制剂而产生潜在感染。
3.避免因机械性屏障完整性的损失所致的体液和热量损失。
多孔人造痂(costra)可以促使新组织形成，从而使其自然呼吸：其在再生过程中，通过避免破坏过程(如坏死或厌氧菌的产生)实现快速结痂，不需要覆盖和进行进一步处理，直到所述“痂”自然剥离。
3.发明目的
1.人造痂可以防止受损处感染和流体损失，从而加速结痂并使得新组织没有缺陷。
降低传统材料的成本，因为一旦痂形成，没有必要做进一步的处理，且痂可以自然剥离。
4.发明内容
由于反应是由5物质组合在容器中发生的，从而可以形成水溶性触变流体。其中5种物质包括：1和5g％之间的偶氮磺酰胺，0.004和0.007g％之间的龙胆紫，0.001和0.003g％之间的地塞米松，0.5和2g％之间的泛醇，0.03和0.06g％之间的红色庆大霉素，在12～15℃温度下，保存在通过螺帽或压塑封闭的焦糖着色玻璃瓶中，该制剂的原始特性能保持两年。
用户应该注意的是，在广泛损伤的情况下，该红色液体通过微红色的尿液排出，这是对人体无害的。
去除坏死组织，清洗，用石油醚进行脱脂和干燥。
首先摇动容器，采用干净的金属刮刀或通过喷雾将其应用在受伤表面上。
其可以应用在眼睛，耳朵和粘膜上，不需要使用清洗溶剂且没有风险。
一旦应用在生物体组织的表面上，由于酶催化作用会发生物理化学反应，通过反应性基团之间的离子键和共价键产生半紧的网状物。
通过上述暴露的组织将网状物粘接在受损的组织上。
采用下图来表示最可能的结构。
d-泛醇氧化酶促地形成泛酸。
这种酸可以反应以便形成辅酶A的部分，或促使其结合到在该方案中提到的网状物。
磺酰基，羧基，伯或仲羟基酚基或醇基可与暴露的活性蛋白质或氨基糖基团反应，使痂粘接在受损皮肤上且使其保持高浓度。
分子内或分子间及离子型或共价型力赋予结构以强度。
通过疏水相互作用、永久或诱导的偶极-偶极氢键等键在各个层之间提供众多稳定的交叉，形成网状物的连接。
这将产生一级、二级、三级和四级构象，从而使得该结构具有三维结构。
本发明的范围和在受损组织(附图1)上生产该人造痂的方法已经进行了描述和详细说明，下面声明专利权和所有权：
一种用于保护侵蚀或受伤表面的自固定半透性多孔人造痂，在其保护层下促进新组织的生长(见附图2)。
其为一种组合物，其中所述半透性多孔人造痂为网状物，所述网状物通过在上述化合物应用部位和存在酶催化的受伤部位之间的物理化学反应产生。
其类似于培养的皮肤，为一种化学聚合物，在尽可能多的半透性多孔人造痂中，该半透性多孔人造痂具有目前还不存在“化学纤维网”特征。
其还能防止水、电解质、血浆和蛋白质的损失。
所述的五种物质使其具有能应用在损伤处(A-AB类型烧伤处或伤口)，且能通过受损组织的催化作用发生反应的特性，从而产生保护层，该保护层能防止感染，及血浆和蛋白质的损失。
由于该保护层的保护作用，新组织不会失去其原有的结构。
5.附图说明
图1
图1用于示出皮肤的一度烧伤。
图2
该图的目的是显示对物理化学反应的描述，通过其反应性基团之间的离子键和共价键生成半紧网状物。可以看到在结构的各个组件之间的肽键、疏水作用、极性相互作用、永久或诱导的偶极-偶极键、氢键、酰胺、酯、各种酸基在各个组件之间结合，这会产生一级、二级、三级和四级构象，从而使得结构具有三维结构。
图3
半透性多孔人造痂的最有可能的化学式。
图4
龙胆紫：甲基紫，通常也被称为结晶紫或紫药水，是给一组用作pH指示剂和染料的化学化合物名称。龙胆紫(结晶紫，甲基紫10B，六甲基氯化副品红)是抗真菌剂。
图5
地塞米松：具有作用持续时间长，高抗炎性和免疫抑制能力，以及低盐皮质激素活性的含氟皮质激素。它抑制前列腺素和白三烯，血管中和在炎症和免疫应答的细胞过程的中介物质的合成。
图6
庆大霉素：庆大霉素是一种有杀菌作用的广谱抗菌氨基糖苷类。作用机理：本氨基糖苷类主动穿过细菌膜，它们与一种或多种特异性受体蛋白不可逆结合，该特异性受体蛋白具有亚单位30S的细菌核糖体，它们还干预mRNA(信使RNA)和亚单位30S之间的起始复合物。该DNA会被错误地读取，这会引起非功能蛋白质的生产，多核糖体中分离并且不能够合成蛋白质。这也会引起氨基糖苷类的加速运输，导致的结果是：增加细菌的胞质膜的破裂和随后的细胞死亡。
图7
泛醇：泛醇也称为d-泛醇或羟泛酸，是一种无色，高粘度和相对粘稠液体。它是易溶于水和乙醇(96°)。泛醇易溶于头发溶液的制剂，只要它们是水性、水醇性或水烯(hidropropilen)-醇性溶液。
图8
偶氮磺酰胺：该磺酰胺基本上是磺胺的衍生物，其是PABA结构类似物，其中羧基被磺酰基(SO2NH2)取代。因此，磺胺充当PABA的竞争性拮抗剂，阻止二氢叶酸的合成，在没有该代谢物时，不可能合成核酸，从而抑制细菌生长(抑菌效果)。

Claims (2)

1.一种水溶性触变流体，其特征在于，由以下重量比的组分组成：
1-5％的偶氮磺酰胺，0.004-0.007％的龙胆紫，0.001-0.003％的地塞米松，0.5-2％的泛醇，0.03-0.06％的庆大霉素，余量为水。
2.根据权利要求1所述的水溶性触变流体，其特征在于，用于治疗伤口。
CN201380068529.0A 2012-12-27 2013-11-04 半透性多孔人造痂的形成 Expired - Fee Related CN105073121B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ARP120105043A AR089518A1 (es) 2012-12-27 2012-12-27 Costra artificial porosa semipermeable
AR20120105043 2012-12-27
PCT/PE2013/000010 WO2014104898A2 (es) 2012-12-27 2013-11-04 Formación de costra artificial porosa semipermeable

Publications (2)

Publication Number Publication Date
CN105073121A CN105073121A (zh) 2015-11-18
CN105073121B true CN105073121B (zh) 2018-12-04

Family

ID=49959135

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380068529.0A Expired - Fee Related CN105073121B (zh) 2012-12-27 2013-11-04 半透性多孔人造痂的形成

Country Status (15)

Country Link
US (2) US20160000963A1 (zh)
EP (1) EP2939678B1 (zh)
JP (1) JP6073500B2 (zh)
CN (1) CN105073121B (zh)
AR (1) AR089518A1 (zh)
AU (1) AU2013368699B2 (zh)
BR (1) BR112015014785B1 (zh)
CA (1) CA2896488C (zh)
ES (1) ES2633970T3 (zh)
IL (1) IL239618B (zh)
MX (1) MX2015007747A (zh)
PE (1) PE20160748A1 (zh)
RU (1) RU2015128753A (zh)
UY (1) UY35111A (zh)
WO (1) WO2014104898A2 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238100A (en) * 1963-07-23 1966-03-01 American Maize Prod Co Starch phosphate film composition and method of dressing wounds with same
US3328259A (en) * 1964-01-08 1967-06-27 Parachem Corp Dressing for a wound containing a hemostatic agent and method of treating a wound
US3577516A (en) * 1969-12-02 1971-05-04 Nat Patent Dev Corp Preparation of spray on bandage
CN1698628A (zh) * 2004-05-21 2005-11-23 邹宏 一种美容修护液及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2364563A (en) * 1941-09-25 1944-12-05 John B Stribling Keratitic medicament
US3146162A (en) * 1961-05-05 1964-08-25 Harold A Abramson Gentian violet adsorption complex
US3969498A (en) * 1973-09-13 1976-07-13 University Of The Pacific Dressing and method for treating a wound
JP3261807B2 (ja) * 1992-06-09 2002-03-04 味の素株式会社 チキソトロピーを有するゲル状組成物
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
FR2819721B1 (fr) * 2001-01-19 2005-02-04 L M D Traitement des escarres avec sucre non metabolisable et un absorbant polymerique
US20050031540A1 (en) * 2001-11-20 2005-02-10 Nielsen Per Julius Visco dye
US20030203032A1 (en) * 2002-04-25 2003-10-30 Schultz Clyde L. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
AU2003290517A1 (en) * 2002-08-20 2004-04-19 General Wound Kare, Inc. (A Corporation Of Deleware) Medical pad, and method for making and using
DE10357046A1 (de) * 2003-12-04 2005-06-30 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen enthaltend eine Kombination aus grünem Farbstoff und antiinflammatorischem Wirkstoff
US20070161936A1 (en) * 2006-01-06 2007-07-12 Svetlik Harvey E Wound treatment-dressing and method of manufacture
ES2304103B1 (es) * 2007-02-22 2009-08-07 Biocosmetics S.L. Composicion para tratamiento de la xerostomia o boca seca.
CN103037858A (zh) * 2010-07-02 2013-04-10 华柏恩视觉研究中心 用于预防和治疗接触镜致乳头性结膜炎以及过敏性眼病的组合物
CN101947226A (zh) * 2010-09-10 2011-01-19 李晓倩 治疗红眼病的滴液

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238100A (en) * 1963-07-23 1966-03-01 American Maize Prod Co Starch phosphate film composition and method of dressing wounds with same
US3328259A (en) * 1964-01-08 1967-06-27 Parachem Corp Dressing for a wound containing a hemostatic agent and method of treating a wound
US3577516A (en) * 1969-12-02 1971-05-04 Nat Patent Dev Corp Preparation of spray on bandage
CN1698628A (zh) * 2004-05-21 2005-11-23 邹宏 一种美容修护液及其制备方法

Also Published As

Publication number Publication date
PE20160748A1 (es) 2016-08-21
AU2013368699A1 (en) 2015-07-16
JP2016504357A (ja) 2016-02-12
ES2633970T3 (es) 2017-09-26
AU2013368699B2 (en) 2017-08-10
EP2939678A2 (en) 2015-11-04
WO2014104898A3 (es) 2015-01-08
US20190022274A1 (en) 2019-01-24
BR112015014785B1 (pt) 2021-11-30
IL239618B (en) 2018-01-31
UY35111A (es) 2013-12-31
CN105073121A (zh) 2015-11-18
WO2014104898A2 (es) 2014-07-03
RU2015128753A (ru) 2017-02-01
JP6073500B2 (ja) 2017-02-01
CA2896488A1 (en) 2014-07-03
EP2939678B1 (en) 2017-04-19
MX2015007747A (es) 2015-09-04
CA2896488C (en) 2017-11-21
AR089518A1 (es) 2014-08-27
US20160000963A1 (en) 2016-01-07
IL239618A0 (en) 2015-08-31
EP2939678A4 (en) 2016-06-08
BR112015014785A2 (pt) 2017-08-15

Similar Documents

Publication Publication Date Title
Li et al. Tannic acid/Sr2+-coated silk/graphene oxide-based meniscus scaffold with anti-inflammatory and anti-ROS functions for cartilage protection and delaying osteoarthritis
US20190202998A1 (en) Visible light-curable water-soluble chitosan derivative, chitosan hydrogel, and preparation method therefor
CA2602905A1 (en) Photocrosslinkable oligo(poly (ethylene glycol) fumarate) hydrogels for cell and drug delivery
Giraldo-Gomez et al. Fast cyclical-decellularized trachea as a natural 3D scaffold for organ engineering
WO2003034993A3 (en) Composition and method for growing, protecting, and healing tissues and cells
CN101664562A (zh) 创伤修复水凝胶材料及制备方法
CN106344956A (zh) 一种壳聚糖抑菌促愈合凝胶及其制备方法
CN104740685A (zh) 一种神经修复膜及其制备方法
US20200325249A1 (en) Visible light-curable water-soluble chitosan derivative, chitosan hydrogel, and preparation method therefor
EA014391B1 (ru) Фармацевтическая композиция для лечения ожогов и способ ее получения
CN116390691A (zh) 自组装的两亲性肽水凝胶
Lu et al. Silk fibroin-based tough hydrogels with strong underwater adhesion for fast hemostasis and wound sealing
CN104474573B (zh) 一种生物敷膜及制备方法
ES2285092T3 (es) Preparado para la curacion de heridas y la prevencion de la adhesion del vendaje a la herida.
WO2017101020A1 (zh) 一种改良的敷料
CN102895699A (zh) 一种用于皮肤创伤修复的复合水凝胶敷料的制备方法
CN105073121B (zh) 半透性多孔人造痂的形成
KR101539675B1 (ko) 외상 치료 및 모니터링용 수화겔 패치
Huang et al. Injectable, Water-Reinforceable, and Antibacterial Tissue Adhesive with Underwater Bioadhesion Capability
CN107714677A (zh) 一种液体创面保护膜及其制备方法
JP5138299B2 (ja) 皮膚用剤
Ma et al. In situ photoactivated antibacterial and antioxidant composite materials to promote bone repair
CN106563155A (zh) 一种用于修复皮肤的凝胶的制备方法
CN111840629B (zh) 一种抗菌性蚕茧基伤口敷料的制备方法
CN112316110B (zh) 促进皮肤创伤修复的药物制剂及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181204

Termination date: 20211104

CF01 Termination of patent right due to non-payment of annual fee